About Type 2 Diabetes In the United States alone, nearly 26 million people are affected by diabetes. Type 2 diabetes accounts for 90 to 95 percent of all diabetes cases. Diabetes is emerging as one of the most serious health problems of our time; the number of Americans with diabetes has tripled over the last 30 years.
About Victoza ® Victoza ® (liraglutide [rDNA origin] injection), is the first and only human glucagon-like peptide-1 (GLP-1) analog that is 97 percent similar to endogenous human GLP-1. Like natural GLP-1, Victoza ® works by stimulating the beta cells to release insulin only when blood sugar levels are high. Due to this glucose-dependent mechanism of action, Victoza ® is associated with a low rate of hypoglycemia. The mechanism of blood sugar lowering also involves a delay in gastric emptying.
Victoza ® was approved by the U.S. Food and Drug Administration (FDA) on January 25, 2010, as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes.As of October 2011, Victoza ® has been commercially launched in more than 40 countries globally including the U.S., Canada, Japan, UK, Germany, France, Italy, Denmark, Hungary, Russia, India, Brazil, Mexico, Argentina, the GULF, Malaysia and China as well as a number of other countries, and will be available in other markets throughout 2012. Indications and UsageVictoza ® (liraglutide [rDNA origin] injection) is an injectable prescription medicine that may improve blood sugar (glucose) in adults with type 2 diabetes when used along with diet and exercise. Victoza ® (liraglutide [rDNA origin] injection) is not recommended as the first medication to treat diabetes. Victoza ® is not insulin and has not been studied in combination with insulin. Victoza ® is not for people with type 1 diabetes or people with diabetic ketoacidosis. It is not known if Victoza ® is safe and effective in children. Victoza ® is not recommended for use in children.